Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
Condition: Hemophagocytic Lymphohistiocytosis Interventions: Drug: Ruxolitinib; Drug: Dexamethasone; Drug: Etoposide Sponsors: St. Jude Children's Research Hospital; Incyte Corporation; North American Consortium for Histiocytosis Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials